- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04576091
Test de l'ajout d'un médicament anticancéreux, BAY 1895344, avec radiothérapie au traitement habituel au pembrolizumab pour le cancer récurrent de la tête et du cou
Essai de phase I de l'inhibiteur d'ATR BAY 1895344 associé à la radiothérapie corporelle stéréotaxique et au pembrolizumab pour le carcinome épidermoïde récurrent de la tête et du cou
This phase I trial evaluates the best dose, possible benefits and/or side effects of combination therapy with elimusertib (BAY 1895344), stereotactic body radiation, and pembrolizumab in treating patients with head and neck squamous cell cancer that has come back (recurrent) and cannot be removed by surgery (unresectable). BAY 1895344 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving BAY 1895344, stereotactic body radiation therapy in combination with pembrolizumab may shrink or stabilize head and neck squamous cell cancer for longer than treatment with radiation and immunotherapy without BAY 1895344.
Aperçu de l'étude
Statut
Les conditions
- Carcinome épidermoïde récurrent de la tête et du cou
- Carcinome épidermoïde hypopharyngé récurrent
- Carcinome épidermoïde laryngé récurrent
- Carcinome épidermoïde récurrent de la cavité buccale
- Carcinome épidermoïde oropharyngé récurrent
- Carcinome oropharyngé de stade clinique III médié par le VPH (p16 positif) AJCC v8
- Carcinome oropharyngé de stade clinique IV médié par le VPH (p16 positif) AJCC v8
- Carcinome de l'hypopharynx de stade III AJCC v8
- Cancer du larynx de stade III AJCC v8
- Cancer de la lèvre et de la cavité buccale de stade III AJCC v8
- Carcinome oropharyngé de stade III (p16-négatif) AJCC v8
- Carcinome de l'hypopharynx de stade IV AJCC v8
- Cancer du larynx de stade IV AJCC v8
- Cancer de la lèvre et de la cavité buccale de stade IV AJCC v8
- Carcinome oropharyngé de stade IV (p16-négatif) AJCC v8
- Carcinome épidermoïde de la tête et du cou non résécable
- Carcinome épidermoïde hypopharyngé non résécable
- Carcinome épidermoïde laryngé non résécable
- Carcinome épidermoïde de la cavité buccale non résécable
- Carcinome épidermoïde oropharyngé non résécable
- Cancer sinonasal de stade IV AJCC v8
- Carcinome récurrent des glandes salivaires
- Cancer majeur des glandes salivaires de stade III AJCC v8
- Cancer majeur des glandes salivaires de stade IV AJCC v8
- Cancer naso-sinusien de stade III AJCC v8
- Carcinome épidermoïde récurrent des sinus paranasaux
- Carcinome épidermoïde des sinus paranasaux non résécable
- Carcinome épidermoïde des glandes salivaires non résécable
- Stage IV Head and Nou Cartane cutané CARCINOMA SELLES A AJCC V8
- Carcinome épideronnier cutané récurrent de la tête et du cou
- Stade III Tête et cou CARCINOME SPÉLIQUE CUDAME AUJCC V8
- Unresectable Head and Neck Cutaneous Squamous Cell Carcinoma
Description détaillée
PRIMARY OBJECTIVES:
I. To evaluate the safety and tolerability of BAY 1895344 with concurrent head and neck stereotactic body radiation therapy (SBRT) reirradiation and pembrolizumab.
II. To determine the recommended phase 2 dose (RP2D) of BAY 1895344 in combination with concurrent head and neck SBRT and pembrolizumab.
SECONDARY OBJECTIVE:
I. To observe and record anti-tumor activity (overall response rate, progression-free survival, and overall survival) of BAY 1895344, SBRT, and pembrolizumab for recurrent head and neck squamous cell carcinoma (HNSCC).
EXPLORATORY OBJECTIVE:
I. To identify predictive biomarkers of response to BAY 1895344, SBRT, and pembrolizumab, including, but not limited to the following: genetic alterations of ATM and other deoxyribonucleic acid (DNA) damage response genes, tumor mutational load, circulating tumor DNA, baseline tumor ATM mutation status, tumor PD-L1 expression, and change in circulating Ki67+ CD8+ T-cells relative to baseline.
OUTLINE: This is a dose-escalation study of BAY 1895344 and stereotactic body radiation therapy (SBRT) given with fixed-dose pembrolizumab.
Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1 of each cycle. Starting on day 7, patients also receive BAY 1895344 orally (PO) twice daily (BID) on days 7-9 and 14-16 during cycle 1, and before and after each SBRT treatment during cycle 2 for a total of 9 doses. Beginning cycle 2, patients undergo SBRT starting between days 2 and 8 for 3 fractions with 2-3 days between fractions. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) scan and/or positron emission tomography (PET)-CT scan and collection of blood samples throughout the trial.
After completion of study treatment, patients are followed up every 13 weeks for at least 24 months.
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
California
-
Los Angeles, California, États-Unis, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, États-Unis, 90033
- Los Angeles General Medical Center
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Northwestern University
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109
- University of Michigan Rogel Cancer Center
-
-
New York
-
The Bronx, New York, États-Unis, 10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx, New York, États-Unis, 10467
- Montefiore Medical Center - Moses Campus
-
-
North Carolina
-
Durham, North Carolina, États-Unis, 27710
- Duke University Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73104
- University of Oklahoma Health Sciences Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, États-Unis, 15232
- UPMC Hillman Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84112
- Huntsman Cancer Institute/University of Utah
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Patients must have histologically confirmed recurrent or metachronous (second primary), unresectable head and neck squamous cell carcinoma, including oral cavity, oropharynx, larynx, hypopharynx, cutaneous, salivary gland, paranasal sinus, or cervical lymphadenopathy (head and neck cancer of unknown primary). Core needle biopsy (preferably at least three 18-gauge cores) or incisional biopsy is preferred over fine needle aspiration (FNA) for diagnosis of recurrent disease or new primary head and neck squamous cell carcinoma to provide sufficient tumor tissue for correlative studies. Unresectable refers both to patients who have declined surgery and patients deemed unresectable by otolaryngology. This includes patients for whom curative resection is medically contraindicated and/or would be associated with excessive surgical risk (as deemed by the consulting otolaryngologist) or undue surgical morbidity (e.g., total glossectomy, laryngectomy, and/or major resection requiring free flap reconstruction)
-
Patients must have either recurrent disease or a new primary squamous cell carcinoma of the head and neck within a previously irradiated area (radiotherapy to dose >= 40 Gy, i.e., in-field recurrence)
-
Patients must have completed prior radiotherapy >= 6 months prior to enrollment
-
Patients must meet at least one of the following criteria: 1) received prior platinum-containing chemotherapy; and/or 2) tumor expresses PD-L1 (Combined Positive Score [CPS] >= 1)
-
Patients who have received anti-PD-1, anti-PD-L1, or anti-PD-L2 therapy must have had disease progression while on this therapy. Patients who have not received prior anti-PD-1, anti-PD-L1, or anti-PD-L2 therapy are also eligible
-
Age >= 18 years. Because no dosing or adverse event data are currently available on the use of BAY 1895344 with pembrolizumab in patients < 18 years of age, children are excluded from this study
-
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 50%) and a life expectancy of >= 3 months
-
Leukocytes >= 3,000/mcL
-
Absolute neutrophil count >= 1,500/mcL
-
Platelets >= 100,000/mcL
-
Hemoglobin >= 9 g/dL or 5.6 mmol/L without transfusion or erythropoietin dependency (within 7 days of assessment)
-
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (If total bilirubin > 1.5 x ULN, direct bilirubin must be < ULN)
-
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN (=< 5 x ULN for patients with liver metastases)
-
Creatinine OR measured or calculated creatinine clearance (CrCl) < 1.5 x institutional ULN OR glomerular filtration rate (GFR) > 60 mL/min/1.73 m^2
- CrCl should be calculated per institutional standard
-
Albumin > 2.5 mg/dL
-
International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants
-
Activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
-
Patients must have measurable disease (at least one measurable lesion) as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Baseline imaging must include neck CT (preferably contrast-enhanced) and chest CT or skullbase to midthigh PET/CT (preferably with contrast-enhanced neck CT if diagnostic contrast-enhanced neck CT not available). Patients who have undergone surgery aside from biopsy may be included if gross disease is present within the surgical resection bed or at another site
-
Patients must have no contraindications to pembrolizumab, including no history of organ allograft transplantation or active autoimmune disease (active defined as having autoimmune disease-related symptoms and detectable autoantibodies) that has required systemic treatment in the past 2 years (i.e., use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
-
Human immunodeficiency virus (HIV)-infected patients may participate IF they meet the following eligibility requirements:
- They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective
- They must have a CD4 count of greater than 250 cells/mcL
- They must not be receiving prophylactic therapy for an opportunistic infection
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy (e.g., not hepatitis B surface antigen [HBsAg] reactive), if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load (e.g., HCV ribonucleic acid [RNA] [qualitative] is not detected)
-
Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging using the identical imaging modality for each assessment, either magnetic resonance imaging [MRI] or computed tomography [CT] scan, for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial (e.g. basal cell carcinoma, early-stage differentiated thyroid carcinoma, low-risk prostate cancer, ductal carcinoma in situ of the breast, squamous cell carcinoma of the skin that has undergone potentially curative therapy, in situ cervical cancer). Patients with 10 or fewer distant metastases may be eligible for this trial if they meet performance status inclusion criteria
-
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association functional classification. To be eligible for this trial, patients should be class 2B or better
-
Enrolling site must perform PD-L1 testing on tumor biopsy per institutional protocol (local testing or tissue sent to outside laboratory for PD-L1 immunohistochemistry (IHC) 22C3 pharmDx). Combined positive score (CPS) is recommended for PD-L1 scoring. Test result does not need to be available at the time of enrollment and treatment initiation, unless the patient has not received prior platinum-containing chemotherapy. For patients without a history of platinum-containing chemotherapy, PD-L1 testing with CPS >= 1 is required to be eligible to receive pembrolizumab
-
Female patients of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. The effects of BAY 1895344 on the developing human fetus are unknown. For this reason and because DNA-damage response inhibitors as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 6 months after completion of BAY 1895344 therapy or 4 months after completion of pembrolizumab therapy, whichever is later. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of BAY 1895344 therapy or 4 months after completion of pembrolizumab therapy, whichever is later
- Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient
-
Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible
Exclusion Criteria:
-
Patients who are unable to take oral medications
-
Patients with nasopharyngeal carcinoma, paranasal sinus cancers with histology other than squamous cell carcinoma, or salivary gland cancers with histology other than squamous cell carcinoma
-
Patients who have had more than one prior course of head and neck radiotherapy
-
Patients who have disease surrounding >= 180 degrees of the carotid artery
-
Patients with gross tumor involvement of the mandible
-
Patients with widely metastatic disease.
- Note: Patients with oligometastatic disease (defined as ten or fewer distant metastases) may qualify for the study
-
Patients who have had chemotherapy, targeted small-molecule therapy, or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
- Note: Patients with =< grade 2 neuropathy or =< grade 2 alopecia are an exception to this criterion and may qualify for the study
- Note: If patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
-
Patients who are currently participating and receiving study therapy or have participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
-
Has received transfusion of blood products (including platelets or red blood cells) or administration of colony stimulating factors (including granulocyte colony-stimulating factor [G-CSF], granulocyte macrophage colony-stimulating factor [GM-CSF], or recombinant erythropoietin) within 4 weeks prior to initiating the study drug BAY 1895344
-
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. The use of physiologic doses of corticosteroids may be approved after consultation with the study principal investigator (PI)
-
Has had a prior monoclonal antibody other than anti-PD-1, anti-PD-L1, or anti-PD-L2 therapy within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events (AEs) due to agents administered more than 4 weeks earlier.
Note: Patients who received anti-PD-1, anti-PD-L1, or anti-PD-L2 therapy within 4 weeks prior to study initiation are eligible if they have exhibited disease expression while on this therapy
- Has new or progressive brain metastases, or leptomeningeal disease
- Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, in situ cervical cancer, ductal carcinoma in situ of the breast, early-stage differentiated thyroid cancer, or low-risk prostate cancer. Note: As discussed above, patients with limited metastatic disease (10 or fewer distant metastases) may qualify for the study
- Patients with carcinomatous meningitis should be excluded
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to BAY 1893544 or pembrolizumab
- Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
- Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
- Patients whose disease has improved or remained stable (no evidence of disease progression) while receiving therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent are ineligible
- Patients receiving any medications that are substrates of CYP3A4 with a narrow therapeutic window, or strong inhibitors/inducers of CYP3A4 are ineligible, if they cannot be transferred to alternative medication. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
- Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Patients with psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study because BAY 1895344 as a DNA-damage response inhibitor may have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with BAY 1895344, breastfeeding should be discontinued if the mother is treated with BAY 1895344 and for 4 months after the end of BAY 1895344 treatment. These potential risks may also apply to other agents used in this study
- Has a known history of active tuberculosis (TB)
- Has received a live vaccine within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted. Similarly, coronavirus disease 2019 (COVID-19) vaccines are permitted
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Treatment (pembrolizumab, BAY 1895344, SBRT)
Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Starting on day 7, patients also receive BAY 1895344 PO BID on days 7-9 and 14-16 during cycle 1, and before and after each SBRT treatment during cycle 2 for a total of 9 doses. Beginning cycle 2, patients undergo SBRT starting between days 2 and 8 for 3 fractions with 2-3 days between fractions. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan and/or PET-CT scan and collection of blood samples throughout the trial. |
Ancillary studies
Autres noms:
Undergo blood sample collection
Autres noms:
Given IV
Autres noms:
Undergo SBRT
Autres noms:
Given PO
Autres noms:
Undergo CT and/or PET-CT scan
Autres noms:
Undergo PET-CT scan
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Maximum-tolerated Dose (MTD) (Escalation)
Délai: Up to 6 weeks
|
Dose of elimusertib (BAY 1895344) and concurrent stereotactic (8 Gy x 3 RT) body radiation therapy. Two 3-week cycles of therapy. |
Up to 6 weeks
|
|
Incidence of Dose Limiting Toxicities (DLT)
Délai: Within 90 days of treatment initiation
|
Number of patients who experienced Dose Limiting Toxicities. DLTs are defined as occurrence of any of the following events, if judged by the Investigator to be possibly, probably or definitely related to study drug administration
|
Within 90 days of treatment initiation
|
|
Dose of BAY 1895344
Délai: Up to 6 weeks
|
Dose of elimusertib (BAY 1895344) and concurrent stereotactic (8 Gy x 3 RT) body radiation therapy. Two 3-week cycles of therapy. |
Up to 6 weeks
|
|
Incidence of Late Adverse Events
Délai: After 90 days post discontinuation of treatment, up to 1 year
|
Number of patients that experienced Adverse Events and/or Serious Adverse Events assessed per Common Terminology Criteria for Adverse Events (CTCAE) version 5, at least possibly related to treatment. |
After 90 days post discontinuation of treatment, up to 1 year
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of Adverse Events
Délai: Up to 12 months
|
Number of patients that experienced AEs and/or SAEs per CTCAE version 5 at least possibly related to treatment. |
Up to 12 months
|
|
Locoregional Control
Délai: Up to 2 years
|
A competing risk analysis will be conducted with local failure, distal failure, and death as competing events. The cumulative incidence and 95% confidence interval for local failure will be estimated. Time to each event will be measured from the start of treatment regimen (day 1 pembrolizumab). |
Up to 2 years
|
|
Overall Response Rate
Délai: Up to 2 years
|
Number of patients experiencing Complete response or partial response per Response Evaluation Criteria in Solid Tumors 1.1 criteria. Per RECIST v1.1: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (target or non-target) with reduction in short axis to <10 mm. Partial Response (PR): ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD):≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression. |
Up to 2 years
|
|
Progression-free Survival
Délai: Up to 2 years
|
Median time from start of treatment regimen (day 1 pembrolizumab) until documented local or distal failure or death from any cause. Will be estimated using the method of Kaplan-Meier. Per RECIST 1.1, Disease Progression is defined as ≥20%increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression. |
Up to 2 years
|
|
1-year Progression-free Survival
Délai: At 1 year
|
Percentage of patients alive without disease progression at 1 year. Per RECIST 1.1, Disease Progression is defined as ≥20%increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression. |
At 1 year
|
|
2-year Progression-free Survival
Délai: At 2 years
|
Percentage of patients alive without disease progression at 2 years. Per RECIST 1.1, Disease Progression is defined as ≥20%increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression. |
At 2 years
|
|
Overall Survival
Délai: Up to 2 years
|
Median time from start of treatment regimen (day 1 pembrolizumab) until death from any cause. Will be estimated using the method of Kaplan-Meier. |
Up to 2 years
|
|
1-year Overall Survival
Délai: Up to one year
|
Percentage of patients alive at one-year post treatment. |
Up to one year
|
|
2-year Overall Survival
Délai: Up to two years
|
Percentage of patients alive at two years post treatment. |
Up to two years
|
|
Functional Assessment of Cancer Therapy - Head and Neck Cancer (FACT-H&N) Score
Délai: At Baseline prior to start of treatment
|
The FACT-H&N (v4) consists of a cancer-specific questionnaire, FACT-G, in addition to 12 H&N cancer specific items (the HN subscale, scores 0 to 40). FACT-G is a 27-item measure that assesses general cancer quality of life. The FACT-G contains 4 subscales: physical, social/family, emotional, and functional well-being. Patients indicate how true 27 statements are for them during the past 7 days. Responses range from not at all (0), to very much (4) on a 5-point scale, with total scores of 0 to 108. Total scores for the 39 items range from 0 to 148 with higher scores indicating better quality of life. |
At Baseline prior to start of treatment
|
|
Functional Assessment of Cancer Therapy - Head and Neck Cancer (FACT-H&N) Score
Délai: At 3 months from start of treatment
|
The FACT-H&N (v4) consists of a cancer-specific questionnaire, FACT-G, in addition to 12 H&N cancer specific items (the HN subscale, scores 0 to 40). FACT-G is a 27-item measure that assesses general cancer quality of life. The FACT-G contains 4 subscales: physical, social/family, emotional, and functional well-being. Patients indicate how true 27 statements are for them during the past 7 days. Responses range from not at all (0), to very much (4) on a 5-point scale, with total scores of 0 to 108. Total scores for the 39 items range from 0 to 148 with higher scores indicating better quality of life. |
At 3 months from start of treatment
|
|
Functional Assessment of Cancer Therapy - Head and Neck Cancer (FACT-H&N) Score
Délai: At 6 months from start of treatment
|
The FACT-H&N (v4) consists of a cancer-specific questionnaire, FACT-G, in addition to 12 H&N cancer specific items (the HN subscale, scores 0 to 40). FACT-G is a 27-item measure that assesses general cancer quality of life. The FACT-G contains 4 subscales: physical, social/family, emotional, and functional well-being. Patients indicate how true 27 statements are for them during the past 7 days. Responses range from not at all (0), to very much (4) on a 5-point scale, with total scores of 0 to 108. Total scores for the 39 items range from 0 to 148 with higher scores indicating better quality of life. |
At 6 months from start of treatment
|
|
Functional Assessment of Cancer Therapy - Head and Neck Cancer (FACT-H&N) Score
Délai: At 12 months from start of treatment
|
The FACT-H&N (v4) consists of a cancer-specific questionnaire, FACT-G, in addition to 12 H&N cancer specific items (the HN subscale, scores 0 to 40). FACT-G is a 27-item measure that assesses general cancer quality of life. The FACT-G contains 4 subscales: physical, social/family, emotional, and functional well-being. Patients indicate how true 27 statements are for them during the past 7 days. Responses range from not at all (0), to very much (4) on a 5-point scale, with total scores of 0 to 108. Total scores for the 39 items range from 0 to 148 with higher scores indicating better quality of life. |
At 12 months from start of treatment
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Potential Predictive Biomarkers of Response
Délai: Up to 2 years
|
Will investigate the association between potential predictive biomarkers of response to treatment. Tumor mutation burden will be categorized as high (above median) or low (equal to or below median). Other biomarker expression levels will be categorized as high versus absent/reduced. The chi-square or Fisher exact test will be used to study associations between expression levels and tumor response (complete response/partial response; stable/progressive disease). Associations with time-to-event endpoints will be investigated using the log rank test. Differences in change in circulating Ki67+ CD8+ T-cells relative to baseline between levels of tumor response will be explored using the t-test or non-parametric equivalent (e.g., Mann-Whitney) if appropriate. Cox regression will be used to explore associations between change in in circulating Ki67+ CD8+ T-cells and time-to-event endpoints. Other biomarkers will be analyzed similarly. |
Up to 2 years
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Yvonne M Mowery, University of Pittsburgh Cancer Institute LAO
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies de la bouche
- Maladies stomatognathiques
- Tumeurs par site
- Tumeurs
- Maladies des voies respiratoires
- Tumeurs par type histologique
- Tumeurs de la tête et du cou
- Tumeurs, glandulaires et épithéliales
- Tumeurs des voies respiratoires
- Maladies oto-rhino-laryngologiques
- Maladies des glandes salivaires
- Tumeurs pharyngées
- Tumeurs oto-rhino-laryngologiques
- Maladies pharyngées
- Carcinome épidermoïde
- Maladies laryngées
- Carcinome épidermoïde de la tête et du cou
- Carcinome
- Tumeurs laryngées
- Tumeurs de la bouche
- Tumeurs oropharyngées
- Tumeurs des glandes salivaires
- Tumeurs hypopharyngées
- Techniques d'investigation
- Thérapeutique
- Techniques de laboratoire clinique
- Techniques et procédures de diagnostic
- Diagnostic
- Procédures chirurgicales, opératoires
- Techniques de chimie, analytique
- Analyse du spectre
- Radiothérapie
- Techniques stéréotaxiques
- Procédures neurochirurgicales
- Manipulation des échantillons
- pembrolizumab
- Spectroscopie de résonance magnétique
- Radiochirurgie
- Baie 1895344
Autres numéros d'identification d'étude
- NCI-2020-07522
- UM1CA186690 (Subvention/contrat des NIH des États-Unis)
- NCI-2020-07522 (Identificateur de registre: CTRP (Clinical Trial Reporting Program))
- 10405 (Autre identifiant: CTEP)
- PRO00107885
- 10405 (Autre identifiant: UPMC Hillman Cancer Center LAO)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .